Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Drug: Insulin glulisine (U300)Drug: NPH insulin
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT02910518
- Locations
- 🇩🇪
Investigational Site Number 276001, Neuss, Germany
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
- Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 448
- Registration Number
- NCT02898454
- Locations
- 🇺🇸
Investigational Site Number 8400011, Fresno, California, United States
🇦🇷Investigational Site Number 0320005, Caba, Argentina
🇦🇷Investigational Site Number 0320004, Buenos Aires, Argentina
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Hypercholesterolaemia
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 42
- Registration Number
- NCT02890992
- Locations
- 🇨🇿
Investigational Site Number 2030002, Zlin, Czechia
🇺🇸Investigational Site Number 8400005, Charlotte, North Carolina, United States
🇺🇸Investigational Site Number 8400001, Cincinnati, Ohio, United States
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
- Interventions
- Biological: CaplacizumabOther: Standard of Care
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 104
- Registration Number
- NCT02878603
- Locations
- 🇬🇧
Investigator site, Liverpool, United Kingdom
🇬🇧Investigator Site, London, United Kingdom
🇫🇷Investigator site 1, Paris, France
Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis
- Conditions
- Secondary Hyperparathyroidism-Chronic Kidney Disease
- Interventions
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT02859896
- Locations
- 🇺🇸
Investigational Site Number :8400025, Greenville, North Carolina, United States
🇺🇸Investigational Site Number :8400015, Jackson, Mississippi, United States
🇺🇸Investigational Site Number :8400021, Syracuse, New York, United States
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 604
- Registration Number
- NCT02855684
- Locations
- 🇨🇳
Investigational Site Number 1560016, Changzhou, China
🇨🇳Investigational Site Number 1560001, Beijing, China
🇨🇳Investigational Site Number 1560039, Beijing, China
Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 11
- Registration Number
- NCT02842359
- Locations
- 🇰🇷
Korea, Seoul, Korea, Republic of
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 892
- Registration Number
- NCT02836704
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 36
- Registration Number
- NCT02812706
- Locations
- 🇯🇵
Investigational Site Number :392012, Chuo-ku, Tokyo, Japan
🇯🇵Investigational Site Number :392003, Okayama-shi, Okayama, Japan
🇯🇵Investigational Site Number :392009, Osaka-shi, Osaka, Japan
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 23
- Registration Number
- NCT02803918
- Locations
- 🇺🇸
Investigational Site Number 840006, New Orleans, Louisiana, United States
🇹🇷Investigational Site Number 792002, Ankara, Turkey
🇺🇸Investigational Site Number 840002, Baton Rouge, Louisiana, United States